Dynavax Technologies Corporation Message Board
stocks_investor
8 posts | Last Activity: May 9, 2013 4:54 PM
Member since: Sep 3, 2009
-
-
Great job self launch
-
tier 2 will rock short term
-
and not based on sales from Amarin to such wholesalers. During the quarter ended March 31, 2013, the net value of Vascepa sold to wholesalers was $5.2 million, which, in accordance with GAAP, resulted in $2.9 million of deferred product revenue from Vascepa sales in the quarter ended March 31, 2013.
-
sNDA changed many big pharma hearts....watch the stock next 2 hrs going up to $9 ha ha
-
-
No news to anyone that self launches are slow compared with major pharma
Drug works period and no better subsitutue in the market. Today is a good day to buy if you want to hold thru 2013, good luck! -
Monday, NCE or no NCE ;-)